BackPharmigene Overview

Pharmigene Receivables

Track Pharmigene's receivables ($18M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$17.65M
↓ 57.45% YoYΔ $-23.83M vs prior year quarter

Peer trimmed avg / median

Loading

Pharmigene Receivables History

Loading

Pharmigene vs. peers: Receivables Comparison

Loading

Pharmigene Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Pharmigene (7595.TWO) FAQ

The latest receivables for 7595.TWO is $18M as of June 2026. That compares with $41M in the prior-year period — down 57.5% year over year. Investors often review this figure alongside Pharmigene's historical trend and sector peers before judging valuation or financial health.

Over the past year, 7595.TWO's receivables moved from $41M to $18M — a 57.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pharmigene's operating scale or balance-sheet position.

A receivables figure of $18M for 7595.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 7595.TWO's receivables ($18M), review year-over-year change from $41M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.